Arca
Skip to content
Tools
Tools

Thyroid eye disease

Drug research and approvals for thyroid eye disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 70 studies of thyroid eye disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 16 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 70
  • Trials authorized in Canada: 16
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting now

Newest posted first, of 70 recruiting on ClinicalTrials.gov ↗

How its trials ended

149 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 25 whose ending is known, 32% met their primary endpoint, 4% missed it and 64% stopped early.

  • Ongoing5436%
  • Completed, result not reported4329%
  • Status unknown2718%
  • Stopped: other or unclear96%
  • Met its primary endpoint85%
  • Stopped: sponsor or business decision32%
  • Stopped: lack of efficacy21%
  • Stopped: enrollment or feasibility21%
  • Missed its primary endpoint11%

Trials authorized in Canada

The 10 newest of 16; search them all in Canada trials
Oct 30, 2026An open-label, rollover study for participants with thyroid eye disease previously enrolled in amgen-sponsored amg 732 studies and are primary proptosis…Amg 732AmgenPending
Sep 14, 2026A phase 3, randomized, double-mask, placebo-controlled study with open-label extension to evaluate the efficacy and safety of linsitinib in participants with…Linsitinib (VGN-001, ASP7487, OSI-906AA)Sling Therapeutics IncPending
Aug 18, 2026A phase 2a open-label, proof of concept trial to evaluate the efficacy and safety of inebilizumab in participants with active thyroid eye disease (TED)UpliznaAmgenPending
Sep 5, 2025A phase 1/2, randomized, double-masked, placebo-controlled, multicenter study to assess the safety, pharmacokinetics, and efficacy of amg 732 in healthy…Amg 732AmgenOngoing
Feb 25, 2025A phase 3, randomized, double-masked, placebo-controlled, multicenter study to evaluate the eficacy, safety, tolerability, pharmacokinetics, pharmacodynamics,…Efgartigimod PH20 (ARGX-113)argenx USOngoing
Jun 26, 2024A phase 3, randomized, double-masked, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy, safety and tolerability of subcutaneous…TeprotumumabAmgenOngoing
Oct 26, 2023A multicenter phase 2b randomized, double-masked, placebo-controlled dose-ranging study of TOUR006 in participants with thyroid eye diseaseTOUR006Tourmaline BioOngoing
Oct 6, 2023An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal studiesVRDN-001Viridian TherapeuticsPending
Sep 29, 2023A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the…VRDN-001Viridian TherapeuticsPending
Jul 18, 2023A phase III, randomized, double-masked, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of…EnspryngRocheClosed

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Jan 21, 2020TeprotumumabTEPEZZA is indicated for the treatment of Thyroid Eye Disease.Horizon Therapeutics Ireland DACApproved

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Jun 19, 2025TepezzaTeprotumumabAmgen Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.